{"entity":{"id":"nct04834024","kind":"trial","name":"MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma","aka":[],"tldr":"A phase 3 trial of Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide in follicular lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.","summary":"MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma is a phase 3 interventional study registered as NCT04834024 by Beijing Mabworks Biotech Co., Ltd., with 168 participants planned, started 2021-06-02 and due to reach its primary completion in 2025-03. Interventions recorded: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide and lenalinomide.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04834024","url":"https://clinicaltrials.gov/study/NCT04834024"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04834024","phase":"3","setting":"A Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of MIL62 Plus Lenalidomide Versus Lenalidomide in Subjects With Follicular Lymphoma Refractory to Rituximab","sponsor":"Beijing Mabworks Biotech Co., Ltd.","enrolled":168,"outcomes":[]},"route":"/trials/nct04834024/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"company":[{"id":"beijing-mabworks-biotech","kind":"company","name":"Beijing Mabworks Biotech","route":"/companies/beijing-mabworks-biotech/"}]}}